All articles tagged with #egfr mutation
Merck and Daiichi Sankyo have voluntarily withdrawn their Biologics License Application for patritumab deruxtecan for treating EGFR-mutated non-small cell lung cancer after the Phase 3 trial failed to meet overall survival endpoints, despite promising progression-free survival results.
Researchers at the Weizmann Institute of Science have discovered that the biological drug Erbitux may be effective in inhibiting the growth of lung cancer tumors with a specific EGFR gene mutation. In trials on lab mice, Erbitux prevented the tumors from growing, and the researchers plan to assess its effectiveness on lung cancer patients. The drug offers potential for personalized treatment and improved chances of success, particularly for patients with the L858R mutation. If clinical trials replicate the findings, Erbitux could be approved for use as a first-line treatment for this specific mutation, potentially saving lives.
AstraZeneca's lung cancer drug, Tagrisso, has been found to reduce the risk of death by over 50% in patients with early-stage non-small cell lung cancer (NSCLC) who have undergone surgery to remove their primary tumor. The drug was evaluated against a placebo in a 682-patient trial called ADAURA. The trial data establishes Tagrisso as the backbone treatment for EGFR-mutated lung cancer. The drug has already received regulatory approvals across multiple geographies for certain patients with NSCLC who have a mutation of the EGFR gene.
AstraZeneca's lung cancer drug, osimertinib, marketed as Tagrisso, has been found to reduce the risk of death by 51% in patients whose tumours were removed surgically, according to clinical trial data presented at the American Society of Clinical Oncology meeting. The drug targets a particular type of lung cancer in patients suffering from non-small cell cancer, the most common type, and showing a particular type of mutation. The clinical trial included 680 participants at an early stage of the disease, in more than 20 countries.
AstraZeneca's drug, osimertinib, marketed as Tagrisso, has been shown to halve the risk of death from non-small cell lung cancer in patients with a particular type of mutation. The clinical trial included 680 participants at an early stage of the disease, and the result showed that taking the tablet resulted in a 51 percent reduction in the risk of death for treated patients, compared to placebo. The drug helps prevent the cancer from spreading to other parts of the body. Osimertinib is already authorized in dozens of countries for various indications and has already been given to some 700,000 people.
AstraZeneca's lung cancer drug, Tagrisso, has been found to reduce the risk of death by over 50% in patients with early-stage non-small cell lung cancer (NSCLC) who have undergone surgery to remove their primary tumor. The drug was evaluated against a placebo in a 682-patient trial called ADAURA, and the data showed that Tagrisso slashed the risk of death by 51% compared to placebo. The drug is already approved for certain patients with NSCLC who have a mutation of the EGFR gene and is expected to become the backbone treatment for EGFR-mutated lung cancer.